Zymeworks Inc
NASDAQ:ZYME
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aurora Solar Technologies Inc
XTSX:ACU
|
CA |
|
HAKI Safety AB
STO:HAKI B
|
SE |
|
B
|
Binhthuan Agriculture Services JSC
VN:ABS
|
VN |
|
T
|
Turkiye Sigorta AS
IST:TURSG.E
|
TR |
|
Luca Mining Corp
OTC:LUCMF
|
CA |
|
Kingsmen Resources Ltd
XTSX:KNG
|
CA |
|
T
|
Thu Duc Trading and Import Export JSC
VN:TMC
|
VN |
|
Summit Industrial Income REIT
TSX:SMU.UN
|
CA |
|
Vastned Retail NV
AEX:VASTN
|
NL |
Zymeworks Inc
Research & Development
Zymeworks Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zymeworks Inc
NASDAQ:ZYME
|
Research & Development
-$137m
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Zymeworks Inc
Glance View
Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.
See Also
What is Zymeworks Inc's Research & Development?
Research & Development
-137m
USD
Based on the financial report for Dec 31, 2025, Zymeworks Inc's Research & Development amounts to -137m USD.
What is Zymeworks Inc's Research & Development growth rate?
Research & Development CAGR 3Y
13%
Over the last year, the Research & Development growth was -2%. The average annual Research & Development growth rates for Zymeworks Inc have been 13% over the past three years .
